Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, FL.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.
Am J Obstet Gynecol. 2024 Mar;230(3S):S669-S695. doi: 10.1016/j.ajog.2023.02.009. Epub 2023 Jul 13.
This review assessed the efficacy and safety of pharmacologic agents (prostaglandins, oxytocin, mifepristone, hyaluronidase, and nitric oxide donors) and mechanical methods (single- and double-balloon catheters, laminaria, membrane stripping, and amniotomy) and those generally considered under the rubric of complementary medicine (castor oil, nipple stimulation, sexual intercourse, herbal medicine, and acupuncture). A substantial body of published reports, including 2 large network meta-analyses, support the safety and efficacy of misoprostol (PGE1) when used for cervical ripening and labor induction. Misoprostol administered vaginally at doses of 50 μg has the highest probability of achieving vaginal delivery within 24 hours. Regardless of dosing, route, and schedule of administration, when used for cervical ripening and labor induction, prostaglandin E2 seems to have similar efficacy in decreasing cesarean delivery rates. Globally, although oxytocin represents the most widely used pharmacologic agent for labor induction, its effectiveness is highly dependent on parity and cervical status. Oxytocin is more effective than expectant management in inducing labor, and the efficacy of oxytocin is enhanced when combined with amniotomy. However, prostaglandins administered vaginally or intracervically are more effective in inducing labor than oxytocin. A single 200-mg oral tablet of mifepristone seems to represent the lowest effective dose for cervical ripening. The bulk of the literature assessing relaxin suggests this agent has limited benefit when used for this indication. Although intracervical injection of hyaluronidase may cause cervical ripening, the need for intracervical administration has limited the use of this agent. Concerning the vaginal administration of nitric oxide donors, including isosorbide mononitrate, isosorbide, nitroglycerin, and sodium nitroprusside, the higher incidence of side effects with these agents has limited their use. A synthetic hygroscopic cervical dilator has been found to be effective for preinduction cervical ripening. Although a pharmacologic agent may be administered after the use of the synthetic hygroscopic dilator, in an attempt to reduce the interval to vaginal delivery, concomitant use of mechanical and pharmacologic methods is being explored. Combining the use of a single-balloon catheter with dinoprostone, misoprostol, or oxytocin enhances the efficacy of these pharmacologic agents in cervical ripening and labor induction. The efficacy of single- and double-balloon catheters in cervical ripening and labor induction seems similar. To date, the combination of misoprostol with an intracervical catheter seems to be the best approach when balancing delivery times with safety. Although complementary methods are occasionally used by patients, given the lack of data documenting their efficacy and safety, these methods are rarely used in hospital settings.
这篇综述评估了药物(前列腺素、催产素、米非司酮、透明质酸酶和一氧化氮供体)和机械方法(单球囊和双球囊导管、海藻棒、膜剥脱和羊膜穿刺术)以及一般被认为属于补充医学范畴的方法(蓖麻油、乳头刺激、性交、草药和针灸)的疗效和安全性。大量已发表的报告,包括 2 项大型网络荟萃分析,支持米索前列醇(PGE1)用于宫颈成熟和引产的安全性和有效性。阴道给予 50μg 的米索前列醇在 24 小时内阴道分娩的可能性最高。无论剂量、途径和给药方案如何,用于宫颈成熟和引产时,前列腺素 E2 似乎在降低剖宫产率方面具有相似的疗效。在全球范围内,虽然催产素是最广泛用于引产的药物,但它的有效性高度依赖于产次和宫颈状况。催产素在引产方面比期待治疗更有效,与羊膜穿刺术联合使用时,催产素的疗效增强。然而,阴道内或宫颈内给予前列腺素比催产素更有效地引产。单次口服 200mg 米非司酮似乎是宫颈成熟的最低有效剂量。评估松弛素的大部分文献表明,这种药物在用于该适应症时益处有限。尽管宫颈内注射透明质酸酶可能会引起宫颈成熟,但由于需要宫颈内给药,限制了该药物的使用。关于阴道给予一氧化氮供体,包括单硝酸异山梨酯、异山梨醇、硝酸甘油和硝普钠,这些药物副作用发生率较高,限制了其使用。一种合成的吸湿宫颈扩张器已被证明对引产前的宫颈成熟有效。虽然在使用合成吸湿扩张器后可以给予药物,但为了减少阴道分娩的间隔时间,正在探索机械和药物方法的联合使用。将单球囊导管与地诺前列酮、米索前列醇或催产素联合使用可增强这些药物在宫颈成熟和引产中的疗效。单球囊和双球囊导管在宫颈成熟和引产中的疗效似乎相似。迄今为止,米索前列醇与宫颈内导管联合使用似乎是在平衡分娩时间和安全性方面的最佳方法。尽管补充方法偶尔被患者使用,但由于缺乏数据证明其疗效和安全性,这些方法在医院环境中很少使用。